VERVE-301

VERVE-301 is a novel, investigational in vivo gene editing therapy designed as a single-course treatment to permanently inactivate the LPA gene in the liver. Its primary goal is to reduce blood levels of lipoprotein(a) [Lp(a)], which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease (ASCVD), ischemic stroke, thrombosis, and aortic stenosis. The therapy uses Verve’s proprietary GalNAc-LNP delivery technology and incorporates a novel gene editor. By targeting the LPA gene directly at the DNA level, VERVE-301 aims to provide durable reduction of Lp(a) with one-time administration—a significant advance over current lipid-lowering therapies that have minimal or no effect on Lp(a). Development of VERVE-301 is being advanced through an exclusive research collaboration between Verve Therapeutics and Lilly[1][2][4][5][7].